Necitumumab
Generic name: Necitumumab
Brand names: Portrazza
Dosage form: intravenous solution (16 mg/mL)
Drug class:
EGFR inhibitors
Usage of Necitumumab
Necitumumab is a monoclonal antibody that blocks a certain protein in the body that can affect tumor cell growth. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage.
Necitumumab is used to treat a certain type of non-small cell lung cancer. Necitumumab is usually given in combination with other cancer medications.
Necitumumab may also be used for purposes not listed in this medication guide.
Necitumumab side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Some side effects may occur during the injection. Tell your caregiver right away if you feel chilled or feverish, or if you have trouble breathing.
Necitumumab may cause serious side effects. Call your doctor at once if you have:
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common side effects of necitumumab may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Necitumumab
You should not be treated with necitumumab if you are allergic to it.
To make sure necitumumab is safe for you, tell your doctor if you have:
Using necitumumab during pregnancy could harm the unborn baby. Tell your doctor if you are pregnant or plan to become pregnant. Use effective birth control to prevent pregnancy while you are using necitumumab and for at least 3 months after your last dose.
It is not known whether necitumumab passes into breast milk or if it could harm a nursing baby. Do not breast-feed while you are being treated with necitumumab, and for at least 3 months after your last dose.
Relate drugs
- Cetuximab
- Erbitux
- Erlotinib
- Exkivity
- Gefitinib
- Iressa
- Mobocertinib
- Necitumumab
- Osimertinib
- Panitumumab
- Portrazza
- Tagrisso
- Tarceva
- Vectibix
How to use Necitumumab
Usual Adult Dose for Non-Small Cell Lung Cancer:
800 mg IV over 60 minutes on Days 1 and 8 of each 3-week cycle prior to gemcitabine and cisplatin infusionDuration of therapy: Continue until disease progression or unacceptable toxicity.Comments:-For patients who have experienced a previous Grade 1 or 2 infusion-related reaction (IRR), premedicate with diphenhydramine (or equivalent) prior to all infusions of this drug.-For patients who have experienced a second Grade 1 or 2 occurrence of IRR, premedicate for all subsequent infusions, with diphenhydramine (or equivalent), acetaminophen (or equivalent), and Dexamethasone (or equivalent) prior to each infusion of this drug.Use: For first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin
Warnings
Necitumumab can cause your electrolytes to become unbalanced. This can lead to serious heart problems, including cardiac arrest. You will need frequent blood tests to check your electrolytes (calcium, potassium, and magnesium).
What other drugs will affect Necitumumab
Other drugs may interact with necitumumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions